Literature DB >> 16218993

Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.

M J Przydzial1, I D Pogozheva, J C Ho, K E Bosse, E Sawyer, J R Traynor, H I Mosberg.   

Abstract

Using results from our previously reported cyclic opioid peptide series and reliable models for mu-, delta-, and kappa-opioid receptors (MOR, DOR, and KOR, respectively) and their complexes with peptide ligands, we have designed and synthesized a series of cyclic pentapeptides of structure Tyr-C[D-Cys-Phe-Phe-X]-NH2, cyclized via disulfide, methylene, or ethylene dithioethers, and where X = D- or L-Cys; or D- or L-penicillamine (Pen; beta,beta-dimethylcysteine). Determination of binding affinities to MOR, DOR, and KOR revealed that members of this series with X = D- or L-Cys display KOR affinities in the low nanomolar range, demonstrating that a 'DPDPE-like' tetrapeptide scaffold is suitable not only for DOR and MOR ligands, but also for KOR ligands. The cyclic pentapeptides reported here are not, however, selective for KOR, rather they display significant selectivity and high affinity for MOR. Indeed, peptide 8, Tyr-C[D-Cys-Phe-Phe-Cys]-NH2-cyclized via a methylene dithioether, shows picomolar binding affinity for MOR ( = 16 pm) with more than 100-fold selectivity for MOR vs. DOR or KOR, and may be of interest as a high affinity, high selectivity MOR ligand. Nonetheless, the high affinity KOR peptides in this series represent excellent leads for the development of structurally related, selective KOR ligands designed to exploit structurally specific features of KOR, MOR, and DOR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16218993     DOI: 10.1111/j.1399-3011.2005.00295.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  10 in total

1.  Ligand/kappa-opioid receptor interactions: insights from the X-ray crystal structure.

Authors:  Karina Martinez-Mayorga; Kendall G Byler; Austin B Yongye; Marc A Giulianotti; Colette T Dooley; Richard A Houghten
Journal:  Eur J Med Chem       Date:  2013-05-30       Impact factor: 6.514

2.  Cyclic enkephalins with a diversely substituted guanidine bridge or a thiourea bridge: synthesis, biological and structural evaluations.

Authors:  Engin Bojnik; Baptiste Legrand; Youness Touati-Jallabe; Elodie Mauchauffée; Nga N Chung; Peter W Schiller; Sandor Benyhe; Marie-Christine Averlant-Petit; Jean Martinez; Jean-Franćois Hernandez
Journal:  J Med Chem       Date:  2013-07-12       Impact factor: 7.446

3.  Novel Cyclic Biphalin Analogues by Ruthenium-Catalyzed Ring Closing Metathesis: in Vivo and in Vitro Biological Profile.

Authors:  Azzurra Stefanucci; Wei Lei; Stefano Pieretti; Marilisa Pia Dimmito; Grazia Luisi; Ettore Novellino; Michał Nowakowski; Wiktor Koźmiński; Sako Mirzaie; Gokhan Zengin; John M Streicher; Adriano Mollica
Journal:  ACS Med Chem Lett       Date:  2019-03-08       Impact factor: 4.345

Review 4.  Investigational peptide and peptidomimetic μ and δ opioid receptor agonists in the relief of pain.

Authors:  Aswini Kumar Giri; Victor J Hruby
Journal:  Expert Opin Investig Drugs       Date:  2013-12-13       Impact factor: 6.206

5.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

6.  Cyclic opioid peptide agonists and antagonists obtained via ring-closing metathesis.

Authors:  Irena Berezowska; Carole Lemieux; Nga N Chung; Brian C Wilkes; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2009-08-20       Impact factor: 2.817

7.  Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.

Authors:  Jessica P Anand; Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Chem Biol Drug Des       Date:  2012-09-12       Impact factor: 2.817

8.  Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.

Authors:  Aubrie A Harland; Larisa Yeomans; Nicholas W Griggs; Jessica P Anand; Irina D Pogozheva; Emily M Jutkiewicz; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2015-11-13       Impact factor: 7.446

Review 9.  Cyclic Opioid Peptides.

Authors:  Michael Remesic; Yeon Sun Lee; Victor J Hruby
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 10.  Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.

Authors:  Yeon Sun Lee
Journal:  Biomolecules       Date:  2022-09-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.